Make an Enquiry
https://www.infiniumglobalresearch.com/reports/enquiry/1127
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World.
In this section the key trends and market size for each geography is provided over the period of 2016-2024. The countries
covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India,
South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the
European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-
pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and
China. Countries such as the U.S., the U.K., and France among others have reported substantial rise in the obesity population.
Moreover, growing work stress in emerging markets of Asia-pacific is likely to cause rise in obesity cases in the years to come
over the next six years. According to the study North America followed by Europe accounted for the largest market share in
the word anti-obesity prescription drugs market in 2016 and this trend is projected to continue over the forecast period, with
increasing awareness among the people in the U.S. and Canada.
Companies Profiled:
The report provides profiles of the companies in the global anti-obesity prescription drugs market such as, F Hoffmann La
Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, Boehringer
Ingelheim, Alizyme and Others. Recently approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising
interest among obese people.Novo Nordisk, an innovator of drugs in the obesity market, introduces Saxenda in all the major
markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, This Dual therapy can be used for
both obesity and type 2 diabetes is the latest trend in the market.
Table of Contends:
1. Preface
1.1. Report description
Infinium Global Research